Tradestie Institutional Equity Comparison Engine
ANNX vs NUVB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANNX Overall Edge
ANNX Captures Institutional Edge (3โ0 Pillars ยท 2โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Annexon, Inc. Common Stock (ANNX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ANNX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus NUVB at N/M Forward P/E and -61.2% operating margin (+242.6% YoY). In options structure, ANNX sits in BREAKDOWN (24th %ile IV; Dealer Gamma Walls on Pro) against NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ANNX N/M vs NUVB N/M Fwd P/E
Growth & Margin Winner
ANNX
Op Margin 0.0% vs -61.2% ยท YoY +0.0% vs +242.6%
Momentum & Technical Winner
ANNX
1Y -23.6% vs -46.9% ยท 52W Pos 1% vs 2%
Options & Structure Winner
ANNX
BREAKDOWN (24th %ile IV) vs BREAKDOWN (26th %ile IV)
ANNX
NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.10
-9.09% 1D
Market Cap
$650.5M
1M Return
-18.64%
1Y Return
-23.65%
Forward P/E
N/M
Unified AI Score
38.6 / 100
SELL
Tech 25.0
Fund 50.0
Flow 71.0
Mom 55.0
NUVB
NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap
$1.3B
1M Return
-19.15%
1Y Return
-46.85%
Forward P/E
N/M
Unified AI Score
61.0 / 100
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ANNX -23.65%
NUVB -46.85%
Spread: +23.2 pp (ANNX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ANNX TTM Op. Margin: 0.0%
NUVB TTM Op. Margin: -61.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs NUVB. Trailing 12-month operating profitability (ANNX 0.0% vs NUVB -61.2%) and valuation multiples (ANNX N/M vs NUVB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANNX | NUVB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $650.5M | $1.3B | Larger Scale | NUVB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +242.6% | Higher Growth | NUVB |
| Operating Margin (TTM) Profitability | 0.0% | -61.2% | Higher Margin | ANNX |
| Net Profit Margin Profitability | 0.0% | -67.4% | Higher Margin | ANNX |
| Return on Equity (ROE) Capital Efficiency | -130.8% | -49.1% | Higher ROE | NUVB |
| 52-Week Range Position Momentum | 1% ($3โ$7) | 2% ($4โ$10) | Stronger Trend | NUVB |
| Beta / 30D Volatility Risk Regime | 1.67ฮฒ ยท 66% Vol | 1.52ฮฒ ยท 55% Vol | Lower Realized Risk | NUVB |
| Unified Institutional Score Composite Signal | 38.6 / 100 (SELL) | 61.0 / 100 (BUY) | Higher Composite | NUVB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ANNX vs NUVB Buy Guide
ANNX
BREAKDOWN
91d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
24th %ile
IV Regime
Compressed (<25th %ile)
NUVB
BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
26th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ANNX nor NUVB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.